Evidence map›Paper›PMID 40701741›Full record

ReviewBest practice & research. Clinical haematology2025

Cytokines in transplantation tolerance.

Andre Souffrant, Avery Wilson, Bryar Hansen, Katsuhiro Tomofuji, Ryo Otsuka, Gilles Benichou, Thomas Spitzer, Tatsuo Kawai

Abstract readReview
In one paragraph

Review in Best practice & research. Clinical haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Associations ofBiomedicines · 2026
    Article
  2. How Cytokines Regulate Immune Response Toward Chronic Allograft Rejection?Results and problems in cell differentiation · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andre SouffrantMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: asouffrant@mgb.org.
Avery WilsonMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: awilson62@mgh.harvard.edu.
Bryar HansenMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: bhansen4@mgh.harvard.edu.
Katsuhiro TomofujiMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: ktomofuji@mgh.harvard.edu.
Ryo OtsukaMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: rotsuka@mgh.harvard.edu.
Gilles BenichouMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: gbenichou@mgh.harvard.edu.
Thomas SpitzerMassachusetts General Hospital, Center for Clinical Transplant Tolerance, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: tspitzer@mgh.harvard.edu.
Tatsuo KawaiMassachusetts General Hospital, Center for Transplantation Sciences, 55 Fruit St., Boston, MA, 02114, USA. Electronic address: tkawai@mgh.harvard.edu.

Funding

Bcl-2 and Mcl-1 inhibition for induction of hematopoietic chimerism and renal allograft tolerance without myelosuppression in nonhuman primatesR01AI155714 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KAWAI, TATSUO · 2022 to 2025
$4.6M
Targeting innate immunity for induction of robust renal allograft toleranceU01AI174968 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI M. AMIN ARNAOUT, TATSUO KAWAI · 2023 to 2026
$4.3M
NIAID NIH HHS R01 AI155714NIAID NIH HHS U01 AI174968
6 · The paper itself

Abstract

Transplantation tolerance is an immunologic state in which a transplant recipient's immune system does not mount a destructive immune response to an allograft. Tolerance offers an alternative to lifelong immunosuppression, potentially extending both allograft and patient survival by reducing transplant-related morbidity. Currently, the only clinically relevant approaches to achieve allograft tolerance rely on induction of donor hematopoietic chimerism through bone marrow or hematopoietic cell transplantation. There are two known types of T cell tolerance to alloantigens - central and peripheral. In central tolerance, alloantigen presentation in the thymic medulla results in clonal deletion of alloreactive immature lymphocytes. Peripheral tolerance is mediated by development of tolerogenic cell populations such as immature dendritic cells and regulatory T cells which suppress or delete alloreactive immune cells in the periphery. As the signaling molecules secreted by immune cells to orchestrate immune responses, cytokines are important in development of both central and peripheral tolerance and are critical in mediating both allograft rejection and tolerance. Understanding the immunology underlying the effects of cytokines on the immune system can help us to better understand their role in tolerance and to leverage that understanding to more reliably and safely induce transplantation tolerance.

Indexed as

CytokinesGraft RejectionHematopoietic Stem Cell TransplantationT-Lymphocytes, RegulatoryTransplantation ToleranceAnimalsDendritic CellsHumansIsoantigensCytokinesIsoantigensAllograftsChimerismCytokinesHematopoietic cell transplantationImmunityImmunosuppression therapyT-lymphocytesTransplantation tolerance

Identifiers

PMID40701741
PMCPMC13027392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.